When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

How does CRISPR work, and why is editing human embryos so controversial? Explore the science, the risks, and the ethical debates surrounding Dr. He Jiankui’s gene-editing experiment.

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria.

Ever since the development of CRISPR/CAS-based gene editing in 2012, the technology has been increasingly adapted in ...

A research team have recently published their article, "Rationally designed pooled CRISPRi-seq uncovers an inhibitor of ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.08, a high estimate of $13.00, ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated ...

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...